KB-1080

Icatolimab

52642

Home » Icatolimab

Background of Icatolimab

Icatolimab (TAB004/JS004) is a humanized recombinant IgG4 monoclonal antibody against B- and T-lymphocyte attenuation factor (BTLA). In vitro and in vivo studies have shown TAB004 or JS004 can promote antigen specific T cell proliferation and effector function, reduce tumor burden and improve survival in human BTLA knock-in tumor models.

Specifications

Catalog Number	KB-1080
Antibody Name	Icatolimab
Isotype	Human IgG4-S228P, kappa
FC Muations	S228P
Target	BTLA
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA \| FACS
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Bosch F, Dalla-Favera R (2019) Chronic lymphocytic leukaemia: from genetics to treatment. Nat Rev Clin Oncol 16:684–701.
Burger JA, O’Brien S (2018) Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol 15:510–527.